CID-103 (IV)
Antibody-Mediated Rejection (AMR) in Organ Transplant
Phase 1/2Active
Key Facts
Indication
Antibody-Mediated Rejection (AMR) in Organ Transplant
Phase
Phase 1/2
Status
Active
Company
About CASI Pharmaceuticals
CASI Pharmaceuticals' mission is to address urgent unmet medical needs in organ transplant rejection and autoimmune diseases through its lead candidate, CID-103. The company has established a commercial footprint in China with products like EVOMELA® and FOLOTYN®, generating revenue to support its R&D. Its strategy hinges on advancing CID-103 as a first-in-class therapy for AMR while leveraging its China commercial platform for sustainable growth. Key achievements include building a dual-region management team and advancing CID-103's preclinical and clinical development.
View full company profile